Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP decreased its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 23.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 215,600 shares of the company's stock after selling 64,900 shares during the quarter. Two Sigma Advisers LP owned 0.36% of Twist Bioscience worth $10,019,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Barclays PLC raised its holdings in Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after purchasing an additional 104,420 shares during the period. Vanguard Group Inc. raised its holdings in Twist Bioscience by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after purchasing an additional 189,791 shares during the period. Wells Fargo & Company MN raised its holdings in Twist Bioscience by 34.5% in the 4th quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock worth $1,761,000 after purchasing an additional 9,722 shares during the period. KBC Group NV raised its holdings in Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after purchasing an additional 1,226 shares during the period. Finally, Teacher Retirement System of Texas raised its holdings in Twist Bioscience by 18.9% in the 4th quarter. Teacher Retirement System of Texas now owns 17,357 shares of the company's stock worth $807,000 after purchasing an additional 2,755 shares during the period.

Analysts Set New Price Targets

TWST has been the subject of a number of analyst reports. The Goldman Sachs Group reduced their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Barclays cut their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. JPMorgan Chase & Co. cut their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, Robert W. Baird cut their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience has an average rating of "Moderate Buy" and a consensus target price of $50.40.

Insider Buying and Selling

In related news, CFO Adam Laponis sold 936 shares of the stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total value of $27,846.00. Following the completion of the transaction, the chief financial officer now directly owns 106,018 shares in the company, valued at approximately $3,154,035.50. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $98,265.82. Following the completion of the transaction, the chief executive officer now owns 662,692 shares of the company's stock, valued at $27,110,729.72. The trade was a 0.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 26,011 shares of company stock worth $951,499. Company insiders own 3.01% of the company's stock.

Twist Bioscience Price Performance

Shares of TWST stock traded down $0.38 during trading hours on Wednesday, reaching $29.03. The company had a trading volume of 277,421 shares, compared to its average volume of 1,094,230. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The stock has a fifty day moving average of $36.19 and a 200-day moving average of $42.60. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -8.59 and a beta of 2.54. Twist Bioscience Co. has a 12-month low of $27.12 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The company had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. On average, equities analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.